| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| ETHZilla Corp Com Par $0.0001 | Fibrosis & Anti-TNF | Frozen Shoulder | Phase 2 | Trial Discontinued | Subcutaneous | Orthopedic |
| Eton Pharmaceuticals Inc. | Amglidia (glyburide oral suspension) | Neonatal diabetes mellitus | NDA Filing | Type Meeting | Oral | Endocrinology |
| Eton Pharmaceuticals Inc. | ET-600 | Endocrinology condition | PDUFA | Ongoing | Oral | Endocrinology |
| Eupraxia Pharmaceuticals Inc. | EP-104GI - (RESOLVE) | Eosinophilic esophagitis (EoE) | Phase 2b | Data Released | Intra-articular | Gastroenterology |
| Evaxion A/S | EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab) | Metastatic Melanoma | Phase 2b | Data Released | intravenous | Oncology |
| Evaxion A/S | EVX-02/03 | Resectable melanoma (DNA-based, personalized cancer therapy) | Phase 2b | Trial Planned | Intramuscular | Oncology |
| Evelo Biosciences Inc. | EDP1815 | Atopic dermatitis | Phase 2 | Oral | Immunology | |
| Evelo Biosciences Inc. | EDP1815-205 | COVID-19 | Phase 2 | Oral | COVID-19 |